Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Benzylimidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.96 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.96 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.96 |
| ▸ | QPCT | Q16769 | 1/20 | 0.96 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.96 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.96 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.77 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylimidazole SCHEMBL414 | 0.98 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL22063900 | 0.98 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL31453527 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL29239318 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL16237308 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL411827 | 0.96 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL27803894 | 0.92 | CYP11B1 (0.89) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL28764644 | 0.91 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL27535101 | 0.91 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| Benzylimidazole SCHEMBL28970402 | 0.89 | CYP11B1 (0.83) | CYP11B1CYP11B2CYP19A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855285-B2 | Methods for selective N-9 glycosylation of purines | BRIGHAM YOUNG UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | BRIGHAM YOUNG UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | PNP, SLC29A2, SLC28A2 | CYP11B1 2369/4885CYP11B2 2059/4885CYP19A1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.